Hypertension

Mandibular Advancement vs Continuous Positive Airway Pressure (CPAP) for Blood Pressure Reduction in Patients With Obstructive Sleep Apnea

J Am Coll CardiolPublished Randomised controlled trial

Authors' conclusion

MAD is noninferior to CPAP for reducing 24-hour mean arterial BP in participants with hypertension and increased cardiovascular risk.

Study context

Population
Adults aged ≥40 years with hypertension, increased CV risk and moderate-to-severe obstructive sleep apnea (OSA) (apnea-hypopnea index ≥15 events per hour)321 screened by polysomnography
Participants
220 adults
Comparison
Mandibular advancement device (MAD) vs CPAP
Primary endpoint
Change in 24-hour mean arterial BP from baseline
Follow-up
6 months
Methodological detailsinvestigator-initiated, non-inferiority, 3 public hospitals
  • Investigator-initiated
  • Non-inferiority
  • 3 public hospitals

Primary result

As reported in the abstract

Change in 24-h mean arterial BP, baseline to 6 months
GroupValueP vs baselineNo change from baseline
MADdecrease from baseline 2.5 mm HgP = 0.003
CPAPP = 0.374

Value

MADdecrease from baseline 2.5 mm Hg
CPAP— not stated in the abstract

P vs baseline

MADP = 0.003
CPAP— not stated in the abstract

No change from baseline

MAD— not stated in the abstract
CPAPP = 0.374

Further findings

Secondary ambulatory blood pressure (BP) parameters

Larger reduction with MAD vs CPAP in all secondary ambulatory BP parameters, most pronounced in asleep BP

Daytime sleepiness

Both improved; between-group difference similar
P = 0.384

CV biomarkers

No between-group differences

Original publication

Mandibular Advancement vs CPAP for Blood Pressure Reduction in Patients With Obstructive Sleep Apnea. J Am Coll Cardiol. Published 6 April 2024. doi:10.1016/j.jacc.2024.03.359

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.